Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or metastatic ...

Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

“In clinical trials, TIVDAK demonstrated a superior overall ... The study was conducted by Seagen, which was acquired by Pfizer in December 2023, in collaboration with Genmab, European Network ...

TIVDAK® is the first and only antibody-drug ... The study was conducted by Seagen, which was acquired by Pfizer in December 2023, in collaboration with Genmab, European Network of Gynaecological ...

"In clinical trials, TIVDAK demonstrated a superior overall survival benefit and manageable safety profile compared to chemotherapy, supporting its position to become a potential new standard of ...

Pfizer acquired Seagen in December 2023. Tivdak comprises Genmab’s human monoclonal antibody directed to tissue factor (TF) with the ADC technology of Pfizer, which leverages a protease ...

"In clinical trials, TIVDAK demonstrated a superior overall survival benefit ... The study was conducted by Seagen, which was acquired by Pfizer in December 2023, in collaboration with Genmab, ...

"In clinical trials, TIVDAK demonstrated a superior overall survival benefit and manageable safety profile compared to chemotherapy, supporting its position to become a potential new standard of care ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...